An osteoarthritis trial ravaged by COVID, an FDA rejection, three failed clinical trials in COVID and now this: Ampio’s board is conducting an internal investigation and considering a sale. The ...
Ampio Pharmaceuticals Inc (AMEX:AMPE) shares are trading higher Wednesday after the company announced top-line results from the AP-013 Phase III study of Ampion in patients suffering from severe ...
Ampio Pharmaceuticals Inc's (NYSE: AMPE) independent special Committee of the Ampio Board of Directors has started an internal investigation regarding Ampio's AP-013 trial with the assistance of ...
ENGLEWOOD, Colo., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Ampio Pharmaceuticals, Inc. (the "Company” or "Ampio”) has released the following notice of proposed settlement of derivative actions and demands ...
Ampio reports that due to temperature deviations below product specifications during shipments to the Ampion™ STEP Study clinical sites, release of data will be delayed ENGLEWOOD, Colo., Aug. 21, 2014 ...
Ampio Pharmaceuticals, Inc. develops innovative proprietary drugs for metabolic disease, eye disease, kidney disease, inflammation, CNS disease and male sexual dysfunction. The product pipeline ...
Shares of Ampio Pharmaceuticals (NASDAQ:AMPE) rose sharply Monday morning as the company announced positive results from its drug Optina, an oral treatment for diabetic macular edema. According to the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results